- ICH GCP
- EU-register voor klinische proeven
Laatste proeven
EudraCT Number: 2004-001223-37 | Sponsor Protocol Number: 102038 | Start Date: | ||||||
Sponsor Name: GlaxoSmithKline S.A. | ||||||||
Full Title: Ensayo clínico abierto en fase IV, para evaluar la inmunogenicidad y reactogenicidad de la vacuna combinada DTPa (Infanrix) de GlaxoSmithKline Biologicals administrada como dosis de recuerdo a los ... | ||||||||
Medical condition: Inmunización primaria activa frente a la difteria, tétanos y tosferina en niños, a partir de los 2 meses de edad hasta los 7 años. | ||||||||
|
||||||||
Population Age: Children, Under 18 | Gender: Male, Female | |||||||
Trial protocol: ES (Ongoing) | ||||||||
Trial results: View results |
EudraCT Number: 2005-003279-18 | Sponsor Protocol Number: HLH-2004 | Start Date: | ||||||
Sponsor Name: Barncancerforskningsenheten, Astrid Lindgrens Barnsjukhus | ||||||||
Full Title: HLH-2004. Hemophagocytic Lymphohistiocytosis Study Group. Treatment Protocol of the Second International HLH Study 2004. | ||||||||
Medical condition: Hemophagocytic Lymphohistiocytosis (HLH), a life-threatening disease usually occurring in early childhood. HLH-2004 is an international treatment protocol which will be compared with the previous ... | ||||||||
|
||||||||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |||||||
Trial protocol: NO (Ongoing) | ||||||||
Trial results: (No results available) |
EudraCT Number: 2014-000545-78 | Sponsor Protocol Number: Rempex-505 | Start Date: | ||||||||||||||||
Sponsor Name: Rempex Pharmaceuticals, Inc. | ||||||||||||||||||
Full Title: A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF CARBAVANCE™ (MEROPENEM/RPX7009) COMPARED TO PIPERACILLIN/TAZOBACTAM IN TH... | ||||||||||||||||||
Medical condition: complicated urinary tract infection (cUTI) or acute pyelonephritis (AP) with or without concurrent bacteremia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: HU (Completed) CZ (Completed) SK (Completed) IT (Completed) ES (Completed) PL (Completed) SI (Completed) BG (Completed) GR (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2009-017228-24 | Sponsor Protocol Number: CMM/DM1 | Start Date: | |||||||||||
Sponsor Name: Instituto Científico y Tecnológico de Navarra | |||||||||||||
Full Title: Ensayo clínico de tratamiento de la Diabetes Mellitus tipo 1 autoinmune con células madre mesenquimales autólogas | |||||||||||||
Medical condition: Diatetes mellitus tipo 1 autoinmune | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-023410-31 | Sponsor Protocol Number: PLADSEL | Start Date: | |||||||||||
Sponsor Name: CHU DE POITIERS | |||||||||||||
Full Title: Simplification du test de sensibilité au sel : étude préalable chez l'enfant et l'adulte | |||||||||||||
Medical condition: Hypertension artérielle | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-005571-10 | Sponsor Protocol Number: 03-08-21-12 | Start Date: | ||||||
Sponsor Name: Kennedy Krieger Inst. Johns Hopkins Medicine | ||||||||
Full Title: DEXTROMETORPHAN IN RETT SYNDROME | ||||||||
Medical condition: Rett syndrome (RTT) is a neurological disorder with devastating consequences on the brain. It is characterized by stagnation of development followed by regression, both occurring between age 6 mont... | ||||||||
|
||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Female | |||||||
Trial protocol: NO (Ongoing) | ||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003025-28 | Sponsor Protocol Number: TUD-RELAX1-070 | Start Date: | |||||||||||
Sponsor Name: Technische Universität Dresden | |||||||||||||
Full Title: Phase-I/II trial for relapsed or refractory AML patients combining cytarabine and mitoxantrone with venetoclax | |||||||||||||
Medical condition: Patients 18-75 years with acute myeloid leukaemia (AML) at first or second relapse after intensive chemotherapy including allogeneic stem cell transplantation or primary refractory to standard indu... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-001955-29 | Sponsor Protocol Number: 024PKAN15004 | Start Date: | |||||||||||
Sponsor Name: Retrophin, Inc. | |||||||||||||
Full Title: Efficacy, Safety, and Tolerability of Fosmetpantotenate (RE-024), a Phosphopantothenate replacement therapy, in patients with Pantothenate Kinase-associated Neurodegeneration (PKAN): A Randomized, ... | |||||||||||||
Medical condition: Pantothenate kinase associated neurodegeneration (PKAN), an autosomal recessive genetic disorder, the most common form of Neurodegeneration with Brain Iron Accumulation (NBIA). It is a progressive,... | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Prematurely Ended) GB (Prematurely Ended) CZ (Prematurely Ended) NO (Completed) FR (Completed) PL (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-015767-14 | Sponsor Protocol Number: FER-FID-CHEMO | Start Date: | |||||||||||||||||||||
Sponsor Name: Vifor (International) AG | |||||||||||||||||||||||
Full Title: A randomised controlled parallel group open-label study to evaluate the efficacy and safety of intravenous ferric carboxymaltose versus no treatment in anaemic subjects with lymphoid malignancies... | |||||||||||||||||||||||
Medical condition: Anaemic subjects with lymphoid malignancies and functional iron deficiency receiving chemotherapy | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Completed) SE (Prematurely Ended) AT (Prematurely Ended) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2005-005702-23 | Sponsor Protocol Number: BY217/M2-401 | Start Date: | |||||||||||
Sponsor Name: Nycomed GmbH | |||||||||||||
Full Title: Efficacy of 500µg roflumilast once daily versus placebo over 12 weeks in patients with diabetes mellitus type 2. A double blind, parallel group, phase IIb, proof of concept clinical study | |||||||||||||
Medical condition: Diabetes mellitus type 2 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |